Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pilot Study of FCR001 in Hemoglobinopathies
NCT00777231Phase 2Completed
- Sponsor
- Talaris Therapeutics
- Start
- Jan 2005
- Primary completion
- Aug 2010
- Modality
- Bone Marrow HSCs, Peripheral Blood HSCs
- Countries
- 1
01
Overview
Phase 2, open-label trial of FCR001 in sickle cell disease (SCD), thalassemia and aplastic anemia (4 arms), sponsored by Talaris Therapeutics. Primary endpoint: Level of Donor Chimerism from Enriched Hematopoietic Stem Cell Engraftment at 3 years. Started Jan 2005; status: completed.
02
Drugs
FCR001
03
Conditions
sickle cell disease (SCD)thalassemiaaplastic anemia
Beyond the preview
Go deeper on NCT00777231.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00777231.